Showing 1331-1340 of 4174 results for "".
Inflammatory Responses: Managing Psoriasis in Light of Comorbidities
https://practicaldermatology.com/topics/psoriasis/inflammatory-responses-managing-psoriasis-in-light-of-comorbidities/20440/The accumulated evidence suggests that dermatologists must take an active role in addressing risks.Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.Bimekizumab-bkzx Journal Scan: 4 Clinical Trials
https://practicaldermatology.com/topics/digital-supplement/bimekizumab-bkzx-journal-scan-4-clinical-trials/24128/Speed, depth, and durability from the first dual IL-17A/F inhibitor for the treatment of moderate to severe plaque psoriasis.The Excoriated and Bleeding Edge: Updates in Eczema for the Clinician
https://practicaldermatology.com/topics/general-topics/the-excoriated-and-bleeding-edge-updates-in-eczema-for-the-clinician/21469/Atopic dermatitis continues to present treatment challenges, but a steady juggling of four main components—moisturization, antibiotics, anti-inflammatory, and antipruritics— help to maximize control of the disease.Technology Solutions: Q&A With Nextech's Dr. Jason Handza
https://practicaldermatology.com/topics/practice-management/technology-solutions-q-nextechs-dr-jason-handza/28649/Nextech this year introduced Nextech RCM Professional Billing Services, an addition to their practice management software suite. This solution simplifies insurance billing complexities, helping practices reduce administrative burdens and enhance financial performance through optimized cash flow.Lose Your Inhibitions: Expanding Use of JAK Inhibitors
https://practicaldermatology.com/topics/atopic-dermatitis/lose-your-inhibitions-expanding-use-of-jak-inhibitors/23910/Despite data on safety concerns, dermatologists and patients see benefits.Jejunal Trichobezoar in a 3-year-old Boy; Practice Path MD Pro Tip: Architects
https://practicaldermatology.com/youngmd-connect/resident-resource-center/jejunal-trichobezoar-in-a-3-year-old-boy-practice-path-md-pro-tip-architects/20697/Biologic Therapies for 2013: Do We Use Them Enough?
https://practicaldermatology.com/topics/psoriasis/biologic-therapies-for-2013-do-we-use-them-enough/22931/Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuBiologics for Psoriasis and the Impact of the COVID-19 Pandemic
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-and-the-impact-of-the-covid-19-pandemic/23553/A real-world look at how COVID-19 impacted patient care.